The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
305
5 mg orally once daily for 20 weeks
10 mg orally once daily for 20 weeks
20 mg orally once daily for 20 weeks
Absolute Change From Baseline in 6-minute Walking Distance (6MWD) After 20 Weeks of Treatment
The 6MWD test is designed to evaluate a subject's exercise capacity while performing an everyday activity.
Time frame: Baseline, and up to 20 weeks of treatment
Change From Baseline in Average Weekly Percentage of Maximum Possible Recorded Activity Intensity
AVIVO™ Mobile Patient Management System, a wearable wireless device worn by the subject, was used to monitor subjects' cardiovascular status. The patient's everyday physical activity e.g. duration, intensity, was also tracked by the AVIVO device. For Activity Intensity, the Unit of Measure is "percentage of maximum activity", and length of intervals is "daily".
Time frame: Baseline, and up to 20 weeks of treatment
Measured Values (Log Transformed) and Absolute Change in NT-proBNP From Baseline to 20 Weeks
NT-proBNP = N-terminal pro-hormone b-type natriuretic peptide
Time frame: Baseline, and up to 20 weeks of treatment
Measured Values (Log-transformed) and Absolute Change in High Sensitivity Troponin T (Hs-TNT) From Baseline to 20 Weeks
High sensitivity troponin T (hs-TNT) was measured
Time frame: Baseline, and up to 20 weeks of treatment
Measured Values and Absolute Change in 3 Scores From Kansas City Cardiomyopathy Questionnaire (KCCQ) From Baseline to 20 Weeks: Overall Summary Score, Physical Limitation Score and Total Symptom Score
The KCCQ is the leading health-related quality-of-life measure for patients with chronic heart failure (CHF). It is a 23-item questionnaire that independently measures the impact of patient's heart failure (HF), or its treatment, on 7 distinct domains: 1) Symptom Frequency 2) Symptom Burden 3) Physical Limitation 4) Quality of Life 5) Social Limitations 6) Self-efficacy 7) Symptoms Stability. Overall summary score= mean score of (symptom frequency + symptom burden+ physical limitation + quality of life + social limitation); scores on a scale of 0 to 100, higher scores means better outcome; Physical Limitation: scores on a scale of 0 to 100, higher scores means better outcome; Total symptom score=mean score of (symptom frequency + symptom burden): scores on a scale of 0 to 100, higher scores means better outcome. Positive change means improvement and negative change means deterioration.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
30 mg orally once daily for 20 weeks
40 mg orally once daily for 20 weeks
Orally once daily for 20 weeks
Northwestern University
Chicago, Illinois, United States
St. Louis Heart & Vascular, PC
St Louis, Missouri, United States
BryanLGH Medical Center East
Lincoln, Nebraska, United States
Wake Forest Baptist Health
Winston-Salem, North Carolina, United States
Universitätsklinikum St. Pölten
Sankt Pölten, Lower Austria, Austria
Medizinische Universität Graz
Graz, Styria, Austria
Krankenhaus St. Josef Braunau
Braunau am Inn, Upper Austria, Austria
Krankenhaus der Elisabethinen Linz GmbH
Linz, Upper Austria, Austria
Allgemeines Krankenhaus der Stadt Wien
Vienna, Austria
Krankenhaus Hietzing
Vienna, Austria
...and 66 more locations
Time frame: Baseline, and up to 20 weeks of treatment